GlycoMimetics

Board Description

Carbohydrate mimics (“glycomimetic” compounds) represent an important new class of drugs, and GlycoMimetics, Inc. is positioned to lead this promising field. GlycoMimetics has a specialized platform technology which is producing first-in-class proprietary drug candidates with an initial focus on inflammation, cancer, and infectious disease.

Industry
Pharmaceuticals
Country
United States
State
Maryland